Wedding Ribbon With Sayings

CEUTA OPHTHALMOLOGY EYE: Drops OPHTHALMIC NERVE GROWTH FACTOR IN THE TREATMENT OF GLAUCOMA OPHTHALMOLOGY

www.visionparaiso.com

A team of Italian researchers reported in the August 4 edition of Proceedings of the National Academy of Science (Act of the National Academy of Sciences), evidence shows that eye drops containing nerve growth factor improved the vision in three patients with advanced glaucoma
X
The team of researchers Alessandro Lambiase, Luigi Aloe, Marco Centofanti, Vincenzo Pariso, Flavio Mantelli, Gilberto Bucci, Stefano Bonini, Rita Levi-Montalcini and evaluated Colofrancesco Valeria effects of eye drops based on "Nerve Growth Factor" in a rat glaucoma model and subsequently developed a clinical study of three patients with progressive visual field defects despite control eye pressure.
x
Glaucoma was induced in rats by injection of hypertonic saline episcleral vein. Initially evaluated at 100 and 200 mg / mL on the results in 24 rats, determinándosa most effective dose of 200 mg / mL. A second group underwent histological, biochemical and molecular methods on a group treated for 7 weeks, bringing the best indices in relation to the control group. It was aimed at a slower loss of nerve fibers and cell death by apoptosis in the treated group versus the control group.
x
The clinical study on three patients with advanced glaucoma treated psycho and electrofuncionales parameters analyzed after three months of treatment with topical "Nerve Growth Factor."
x
treated patients showed a long-term improvement of visual field, optic nerve function, contrast sensitivity and visual acuity.
x
Studies seem to show that the factor exerts neuroprotective effects Creimiento Nervous, inhibiting apoptosis in animals with glaucoma. In the 3 patients with advanced glaucoma with topical treatment "Nerve Growth Factor" improved all parameters of visual function.
x
These results may open new therapeutic perspectives in the treatment of glaucoma and other neurodegenerative diseases of the optic nerve.
x
Integrato di Ricerca Center, Department of Ophthalmology, University of Rome "Campus Bio-Medico" and Fondazione Alberto Sordi, 00128 Rome, Italy - Institute of Neurobiology and Molecular Medicine, National Research Council, 00143 Rome, Italy - Department of Ophthalmology, University of Rome "Tor Vergata", 00133 Rome, Italy - Gian Battista Bietti Eye Foundation, Rome, Italy - European Brain Research Institute Foundation, 00143 Rome, Italy.
x
Basic information and guidance. For personalized information consult your ophthalmologist.
x
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

I Have Had A Stroke Card

CEUTA EYES: Encapsulated Cell Technology (ECT) FOR DRY MACULAR DEGENERATION EYE OPHTHALMOLOGY

* *

* *
*







http://www.neurotechusa.com/ect/about_encapsulated_cell_technology.asp

Encapsulated Cell Technology (ECT), developed by the company Neurotech (Rhode Island) has managed to keep the vision in the vast majority of patients who participated in Phase II clinical trial conducted for the treatment of degeneration Macular Seca.
*
So far there is no effective treatment for dry AMD, a leading cause of blindness in people over 55 in developed countries.
*
The 96.3% of patients receiving high dose treatment have maintained stable vision after a follow up of 12 months, although it is the patients with better acuity initial visual (2 / 3 or more) that have benefited most.
*
Patients with stable vision have also developed a thickening of their retinas, which seems aumeto translate a density of photoreceptors. * ECT
The implant is a small device (about the size of a grain of rice) contains cells capable of providing consistently and continuously called ciliary neurotrophic factor protein involved in stabilizing macular.
*
Preclinical studies have been funded by the Foundation Fighting Blindness, like esudios maintains phase II / III for treatment of retinitis pigmentosa, Usher syndrome and coroidemia.
*
The results of these trials will be announced at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) meeting in the month of May in Fort Lauderdale (Florida).
*
View previous post:

http://ojosdeceuta.blogspot.com/2007/01/estado-del-tratamiento-de-la.html
*
Basic Information and Guidance. For a custom Info consult your ophthalmologist.
*

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Appraisal Districts In Scottsdale In Arizona

CEUTA: STEM CELL TRANSPLANT FOR AMD. EYE OPHTHALMOLOGY

+ +

+

+ +

We get questions about the story recently published in many media on Degeneration Treatment MACULAR STEM CELLS.

*

British scientists from University College London (UCL) have developed a treatment study (clinical trial) for Macular Degeneration (AMD) - from the use of stem cells, which could begin to implement by 2015.

*
The study of treatment is to replace the layer of eye cells that have undergone a degenerative process because of the age by new cells derived from embryonic stem cell manipulation.

*

This is a new phase of clinical trial initiated in 2007 (v http://www.fundacion-vision.org.py/docs_v2020/tema227.pdf er). According to Professor Peter Coffey, UCL Institute of Ophthalmology, the tests performed so far in the laboratory have yielded a satisfactory result.

*

The procedure is to generate in the laboratory of RPE cells qa replacement from stem cells. These new cells are then injected into the affected area (macular region).

*

already before the scientists themselves have made cell autotransplantation in patients with good prospects, but it is a complicated intervention they manage a few cells (autologous), which limits its use.

*

aim is to establish a protocol that intervention can be reduced to a 45-minute procedure under local anesthesia.

* Scientists from UCL and Moorfields Hospital, working now to produce cells that can be used clinically with the announced financial support of Pfizer, await first test starting in 2011, once receive authorization medical authorities in the UK.

* Once established steps and protocols is expected that intervention can be reduced to a 45-minute procedure under local anesthesia.

*

Being a trial still in development, is not expected its application to clinical practice until 2015.

*

Basic information and guidance. For personalized information consult your ophthalmologist.

*

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
Eye Center DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira